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Abstract
We aimed to quantitatively assess a possible difference of the neointimal quality between biodegradable polymer- (BP-) 
and durable polymer drug-eluting stents (DP-DESs). We conducted a single-center all-comer prospective cohort study: 
the RESTORE registry (UMIN000033009). All patients who received successful OCT examination at planned 3-month 
follow-up after DES implantation were analyzed. Study population was divided into 2 groups, BP-DES versus DP-DES 
groups. We evaluated standard OCT variables, coverage percent, and the quantitative light property values including light 
intensity, attenuation, and backscatter. We performed OCT analyses of 121 lesions in 98 patients (BP-DES 55 lesions in 51 
patients vs. DP-DES 66 lesions in DP-DES 53 patients). Lesion and procedural characteristics were overall well-balanced 
between both groups. At 3-month follow-up, neointimal thickness (BP-DES 49.3 [38.2, 57.7] µm versus DP-DES 54.7 [45.1, 
70.7] µm, p = 0.059) and coverage percent (BP-DES 94.5 [89.8, 97.0]% vs. DP-DES 95.8 [91.1, 98.1]%, p = 0.083) did not 
significantly differ. Light intensity of superficial neointima in the BP-DES was lower than that in the DP-DES, whereas 
that of deep neointima did not differ between both groups. Both superficial and deep neointima of the BP-DES presented 
significantly lower light attenuation and backscatter than those of the DP-DES did. Almost complete coverage at 3 months 
in both contemporary BP- and DP-DES would support the ultra-short DAPT strategy in the upcoming decade. Neverthe-
less, there was a significant difference in the neointimal characteristics on OCT light property 3 months after BP- versus 
DP-DES implantation.
Trial Registration UMIN000033009.
Keywords Optical coherence tomography · Light property analysis · Drug-eluting stent · Biodegradable polymer · Durable 
polymer
Introduction
The contemporary biodegradable polymer DES (BP-DES) 
has thinner struts and an abluminal very thin coat of biode-
gradable polymer which is fully absorbed in 3–4 months in 
a synchronous way with the drug. Abluminal coating tech-
nology of the contemporary BP-DESs, Synergy™ (Boston 
Scientific Corporation, Natick, MA, USA) and Ultimaster™ 
(Terumo Corp., Tokyo, Japan) is expected to enhance the 
early neointimal coverage. Animal study suggested that the 
technology may promote a more complete and quick heal-
ing process with these stents in acute phase [1]. An imag-
ing study of the Ultimaster™ BP-DES in human presented 
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almost complete coverage of struts at 3-month follow-up 
on optical coherence tomography (OCT) [2], which might 
represent the expected early vessel healing. However, precise 
imaging data of these theoretical benefits of the contempo-
rary BP-DES including strut coverage and neointimal quality 
in comparison with the current durable polymer DES (DP-
DES) is still scarce [3].
Several studies reported the usefulness of OCT light 
intensity, light attenuation and light backscatter to charac-
terize the tissue components of coronary artery [4]. In a 
histological study, it was demonstrated that the increased 
light attenuation and light backscatter were associated with 
lipid-rich plaque and macrophages, while increased light 
intensity was related to tissue maturity [4–6].
We aimed to assess a possible difference of the neointimal 
coverage and its quality between BP- and DP-DESs by a 
quantitative light property analysis on OCT.
Materials and methods
Study design and population
Study design was a single-center prospective cohort 
study: the RESTORE registry (UMIN000033009). In the 
RESTORE registry, all patients treated with current DES 
are planned to perform follow-up imaging evaluation 3 
months and 24 months (± 1 month) after the index pro-
cedure with OCT and coronary angioscopy. The 3-month 
results of coronary angioscopy were reported elsewhere [7]. 
In the present acute-phase OCT analysis, all patients who 
received successful OCT examination at planned 3 months 
follow-up (± 1 month) after the DES implantation in the 
native coronary artery irrespective of clinical presentation 
(silent myocardial ischemia, stable or unstable angina, ST 
elevation myocardial infarction, or non-ST elevation myo-
cardial infarction) without any earlier event of stent failure 
were analyzed. Synergy™ and Ultimaster™ were defined 
as BP-DESs, while Resolute™ zotarolimus-eluting stent 
(Medtronic CardioVascular, CA, USA), Xience™ cobalt 
chromium everolimus-eluting stent (Abbott Vascular, Santa 
Clara, CA, USA) were categorized as DP-DESs. Written 
informed consent was obtained from all enrolled patients. 
This study was approved by the Osaka Police Hospital Ethi-
cal Committee.
Procedure
Percutaneous coronary intervention (PCI) strategy was left 
to the discretion of the individual operators. Dual antiplatelet 
therapy (DAPT, aspirin and  P2Y12 inhibitor) was encour-
aged to keep at least 6 months after the PCI. All patients and 
treating physicians were asked to adhere to the Guideline 
of the Japanese Society of Cardiology in terms of tobacco 
usage, exercise, healthy food intake, maintenance of an ade-
quate body weight, and medications for the achievement of 
target blood lipid concentrations, and blood pressure control.
OCT analysis
Angiographic and OCT imaging follow-up was conducted 
3 months after the index procedure. OCT assessment of the 
stented coronary segment was performed using the OPTIS® 
console and the Dragonfly® catheter (both Abbott Vascular, 
Santa Clara, CA, USA). The off-line OCT measurements 
were performed with QCU-CMS software (version 4.69; 
Leiden University Medical Center, Leiden, the Netherlands) 
by independent investigators (TK, YS, SN, and SS). With 
adjustment for the pullback speed, the analysis of continu-
ous cross-sections was performed at each 1 mm longitu-
dinal interval within the treated segment. Lumen contour 
was defined as the continuous interface between a blood and 
non-blood structure. The endoluminal metallic stent contour 
was delineated by a curvilinear interpolation connecting the 
midpoints of the endoluminal leading edge of the reflec-
tive border. The abluminal stent contour was automatically 
drawn by simulating the virtual contour of the struts. After 
identifying all struts in a cross-section, the abluminal stent 
contour was delineated by a curvilinear interpolation con-
necting the middle points of the abluminal edge of virtual 
metallic struts. Thickness of the virtual strut was determined 
by the reported strut thickness of each stent type (Synergy 
74 µm, Ultimaster 80 µm, Xience 81 µm, Resolute Onyx 
81 µm, Resolute Integrity 91 µm).
In the current study, light property analysis was addition-
ally performed to investigate the neointimal quality quantita-
tively. The dedicated software (QCU-CMS software version 
4.69) was employed for the quantitative light property analy-
sis of the vessel wall. The software was used to calculate 
the attenuation and backscattering coefficients based on a 
depth-resolved model [8]. The following parameters were 
analyzed within the neointimal area of interest defined with 
the contours delineated by the investigators: light intensity 
(no unit), (2) light attenuation  (mm− 1), and (3) backscatter 
(no unit). The light intensity indicates the amount of light 
signal detected at a certain location in the vessel wall based 
on reflection and backscatter. The light attenuation, esti-
mated as the depth-resolved attenuation coefficient in this 
study, indicates how fast the light signal is decayed. It is 
the rate of exponential decreasing intensity related to the 
light propagation depth. Concretely, the total incident light 
power I0 is decreased to be I0/e at depth 1/µt. The backscatter, 
estimated as the depth-resolved backscattering coefficient 
in this study, is related to the efficiency of tissue scattering 
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the light backwards [8]. The neointimal area of interest was 
assessed separately as the following two parts: (1) superficial 
neointima (delineated by the luminal contour and the inter-
polated contour connecting the endoluminal edges of struts 
[endoluminal stent contour]), (2) deep neointima (delineated 
by the endoluminal and abluminal stent contours, excluding 
strut area) (Fig. 1). Each parameter was computed at every 
cross-section as an average in the area of interest. The analy-
sis of continuous cross-sections was performed at each 1 mm 
longitudinal interval within the stented segment. The mean 
value in each stent lesion was calculated as a lesion level 
data. The reproducibility of the neointimal analysis depends 
only on the contour delineation since the software is fully 
automatic. The reproducibility of the OCT standard analysis 
with the current software was published elsewhere [9].
Statistical analysis
Study population was divided into 2 groups, BP-DES (Syn-
ergy™ and Ultimaster™) versus DP-DES (Xience™, Reso-
lute Integrity™ and Resolute Onyx™) groups. Normality 
of data distribution was tested by the Kolmogorov-Smirnov 
test. Data are expressed as mean ± SD or median and inter-
quartile range. Group means for continuous variables with 
normal and non-normal distributions were compared using 
Student’s t-tests and Mann–Whitney U tests, respectively. 
Categorical variables were compared using the Pearson’s 
chi-square test or Fischer’s exact test, as appropriate. Mixed 
linear model with an assumed Gaussian distribution was 
used for the comparisons of continuous light property 
variables to take into an account the clustered nature of > 1 
strut, > 1 cross section, > 1 lesion analyzed from the same 
patients which might result in unknown correlations among 
measurements within the clusters. All statistical analyses 




A total of 110 patients with 133 lesions (mean age 
66.8 ± 9.9 years) were enrolled from May 2016 to April 
2018 (BP-DES 59 patients 63 lesions vs. DP-DES 57 
patients 70 lesions). Six patients had both BP-DES and DP-
DES. Eight lesions in 8 patients and 4 lesions in 4 patients 
were excluded due to insufficient OCT image quality in the 
BP-DES and DP-DES groups, respectively. As a result, we 
performed OCT analyses of 121 lesions in 98 patients (BP-
DES 55 lesions in 51 patients vs. DP-DES 66 lesions in 
DP-DES 53 patients) (Fig. 2). The median invasive imag-
ing follow-up time was 102 days after the index procedure. 
Table 1 shows patient and lesion demographics, risk fac-
tors, and medication. Serum profiles including low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, 
and triglycerides were not different between both groups. 
Lesion and procedural characteristics were overall well-
balanced(Table 2). Approximately half of the lesions were 
Fig. 1  Neointimal area compartments analyzed by optical coherence 
tomography. Image example of OCT at three-month follow-up for 
BP-DES and DP-EES (A). Lumen contour (blue), endoluminal (red) 
and abluminal (green) stent contours were delineated semi-automat-
ically (B). The neointimal area of interest was assessed separately as 
the following two parts: (1) superficial neointima (delineated by the 
luminal contour and the interpolated contour connecting the endo-
luminal edges of struts [endoluminal stent contour]) (yellow area in 
c); (2) deep neointima (delineated by the endoluminal and abluminal 
stent contours, excluding strut area) (blue area in C)
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left anterior descending artery. Only pre-dilatation balloon 
diameter was significantly larger in the DP-DES group than 
in the BP-DES group.
OCT findings at 3‑month follow‑up
Table 3 summarizes the OCT results. Lumen area was com-
parable between both groups. Endoluminal stent area was 
also comparable. The abluminal stent area of DP-DES was 
significantly larger than that of BP-DES. Neointimal thick-
ness (BP-DES 49.3 [38.2, 57.7] µm vs. DP-DES 54.7 [45.1, 
70.7] µm, p = 0.059) and coverage percent (coverage %; BP-
DES 94.5 [89.8, 97.0] % vs. DP-DES 95.8 [91.1, 98.1] %, 
p = 0.083) did not significantly differ between both groups.
Neointimal characteristics on light property analysis
Table 3 and Fig. 3 summarizes the results of OCT analysis. 
Light intensity of superficial neointima in the BP-DES group 
was lower than that in the DP-DES group (120.2 [102.9, 
154.8] vs. 170.9 [117.6, 227.4], p < 0.001), whereas deep 
neointima in the BP-DES showed comparable to that in the 
DP-DES. (189.3 [151.9, 254.7] vs. 210.5 [168.8, 254.6], 
p = 0.474). Light attenuation of both superficial and deep 
neointima in the BP-DES group was significantly lower 
as compare to the DP-DES group (superficial; 0.71 [0.62, 
0.80]  mm− 1 vs. 0.93 [0.71, 1.16]  mm− 1, p < 0.001: deep; 
1.09 [0.96, 1.22] vs. 1.20 [1.05, 1.34]  mm− 1, p = 0.008). 
Backscatter of superficial and deep neointima in the BP-DES 
was also significantly lower than that in the DP-DES group 
(superficial; 4.47 [4.23, 4.76] vs. 5.02 [4.59, 5.51], p < 0.001: 
deep; 5.03 [4.71, 5.28] vs. 5.25 [5.00, 5.57] p = 0.002).
Influencing factors of the neointimal optical 
characteristics at 3‑month follow‑up
To investigate the factors associated with the light character-
istics of the superficial neointima, multivariate analysis was 
Fig. 2  Patient flowchart. A total of 110 patients with 133 lesions were 
enrolled from May 2016 to April 2018. Sufficient image quality of 
OCT was obtained in 121 lesions out of 133 lesions (90.9%). As a 
result, a total of 98 patients with 121 lesions were analyzed (biode-
gradable polymer-DES 55 lesions in 51 patients vs. durable polymer-
DES 66 lesions in 53 patients). *Six patients had both BP-DES and 
DP-DES. OCT optical coherence tomography, DES drug-eluting stent
Table 1  Patients’ characteristics
Data are expressed as mean ± standard deviation, median [interquartile range], and number (percentage)
a Six patients had both BP-DES and DP-DES
BP-DES DP-DES p value
N = 51  patientsa N = 53  patientsa
Age (years) 66.29 ± 9.88, 67.00 [60.00, 74.00] 68.42 ± 10.01, 70.00 [62.00, 76.00] 0.297
Body mass index (kg/m2) 24.38 ± 3.89, 23.80 [21.80, 26.30] 25.21 ± 3.47, 24.40 [22.70, 27.70] 0.124
Male (%) 43/51 (84.3) 44/53 (83.0) 0.999
Diabetes Mellitus (%) 26/51 (51.0) 29/53 (54.7) 0.844
Hypertension (%) 37/51 (72.5) 48/53 (90.6) 0.022
Current smoker (%) 7/51(13.7) 6/53 (11.3) 0.773
Serum lipid profile at 3-month follow-up (mg/dl)
 Low-density lipoprotein cholesterol 85.74 ± 23.38, 83.50 [66.25, 100.50] 81.02 ± 21.31, 79.00 [67.00, 99.00] 0.523
 High-density lipoprotein cholesterol 49.36 ± 14.96, 46.00 [41.25, 55.75] 47.04 ± 12.00, 44.00 [40.00, 54.00] 0.407
 Triglycerides 142.20 ± 75.59, 120.50 [88.50, 178.50] 138.91 ± 78.19, 116.00 [89.00, 173.00] 0.836
Medication at 3-month follow-up
 Statin (%) 38/51 (74.5) 46/53 (86.8) 0.139
 Aspirin (%) 51/51 (100.0) 53/53 (100.0) 0.999
 Clopidogrel (%) 19/51 (37.3) 25/53 (47.2) 0.328
 Prasugrel (%) 29/51 (56.9) 29/53 (54.7) 0.846
 Follow-up duration (day) 108.31 ± 29.82, 102.00 [93.00, 116.00] 102.92 ± 17.69, 102.00 [92.00, 112.00] 0.449
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Table 2  Procedural characteristics
Data are expressed as mean ± standard deviation, median [interquartile range], and number (percentage)
BP stent DP stent p value
N = 55 lesions N = 66 lesions
Acute coronary syndrome (%) 12/55 (21.8) 19/66 (28.8) 0.414
Target vessel
 Right coronary artery (%) 16/55 (29.1) 22/66 (33.3) 0.132
 Left anterior descending artery (%) 24/55 (43.6) 37/66(56.1)
 Left circumflex artery (%) 11/55 (20.0) 5/66 (7.6)
 Left main trunk (%) 4/55 (7.3) 2/66 (3.0)
 Pre-dilatation performed 47/55 (85.5) 60/66 (90.9) 0.580
 Pre-dilatation balloon diameter (mm) 2.53 ± 0.52, 2.50 [2.00, 4.00] 2.85 ± 0.68, 2.62 [2.00, 5.00] 0.009
 Pre-dilatation balloon pressure (atm) 12.50 ± 2.96, 12.00 [6.00, 18.00] 12.42 ± 3.72, 12.00 [4.00, 22.00] 0.900
Stenting
 Stent number 1.16 ± 0.37, 1.00 [1.00, 1.00] 1.30 ± 0.49, 1.00 [1.00, 2.00] 0.100
 Stet diameter (mm) 3.02 ± 0.47, 3.00 [2.75, 3.50] 3.05 ± 0.50, 3.00 [2.50, 3.50] 0.860
 Stent length (mm) 41.08 ± 19.10, 38.00 [28.00, 52.00] 36.67 ± 23.39, 30.00 [22.00, 38.00] 0.253
 Stent implantation pressure (atm) 13.23 ± 2.66, 14.00 [12.00, 14.00] 14.03 ± 2.46, 14.00 [12.00, 16.00] 0.084
 Post-dilatation performed 44/55 (80.0) 53/66 (80.3) 0.999
 Post-dilatation balloon diameter (mm) 3.27 ± 0.63, 3.05 [2.00, 5.00] 3.92 ± 3.75, 3.25 [2.25, 30.00] 0.264
 Post-dilatation pressure (atm) 16.18 ± 4.02, 16.00 [6.00, 22.00] 16.73 ± 3.59, 17.00 [8.00, 22.00] 0.481
Stent type
 Synergy (%) 26/55 (47.3) –
 Ultimaster (%) 29/55 (52.7) –
 Xience (%) – 28/66 (42.4)
 Resolute (%) – 38/66 (57.6)
Table 3  Three-month quantitative neointimal assessments on OCT
Data are expressed as mean ± standard deviation, median [interquartile range]
BP-DES DP-DES p value
N = 55 lesions N = 66 lesions
Stent length (mm) 37.20 ± 12.16, 37.20 [30.00, 43.80] 31.83 ± 14.01, 28.90 [20.60, 38.00] 0.028
Mean lumen area  (mm2) 6.13 ± 2.04, 5.53 [4.80, 7.27] 6.80 ± 2.34, 6.39 [4.99, 7.90] 0.097
Mean endoluminal stent area  (mm2) 6.35 ± 2.05, 6.05 [4.86, 7.65] 7.11 ± 2.30, 6.50 [5.46, 8.19] 0.060
Mean abluminal stent area  (mm2) 7.04 ± 2.15, 6.71 [5.50, 8.42] 7.89 ± 2.41, 7.25 [6.15, 9.02] 0.047
Mean neointimal thickness (µm) 52.49 ± 21.21, 49.33 [38.23, 57.71] 62.79 ± 32.25, 54.76 [45.06, 70.68] 0.059
Coverage percent (%) 92.45 ± 6.37, 94.54 [89.77, 97.04] 94.45 ± 4.56, 95.84 [91.06, 98.05] 0.083
Light property analysis
 Superficial neointima
  Light intensity 130.48 ± 44.23, 120.24 [102.91, 154.76] 178.04 ± 67.07, 170.85 [117.58, 227.36] < 0.001
  Light attenuation 0.73 ± 0.14, 0.71 [0.62, 0.80] 0.94 ± 0.27, 0.93 [0.71, 1.16] < 0.001
  Backscatter 4.50 ± 0.42, 4.47 [4.23, 4.76] 5.00 ± 0.59, 5.02 [4.59, 5.51] < 0.001
 Deep neointima
  Light intensity 201.15 ± 70.64, 189.35 [151.87, 254.67] 209.88 ± 63.10, 210.49 [168.84, 254.58] 0.474
  Light attenuation 1.09 ± 0.20, 1.09 [0.96, 1.22] 1.19 ± 0.22, 1.20 [1.05, 1.34] 0.010
  Backscatter 4.96 ± 0.45, 5.03 [4.71, 5.28] 5.23 ± 0.48, 5.25 [5.00, 5.57] 0.002
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conducted using linear regression analysis (Table 4). BP-
DES usage was significantly and strongly associated with 
lower intensity, lower attenuation, and lower backscatter.
Discussion
Main findings of the present study can be summarized as 
follows: (1) At 3-month follow-up, neointimal thickness and 
coverage % were not significantly different between the BP- 
and the DP-DES groups; (2) light intensity of superficial 
neointima in the BP-DES was lower than that in the DP-
DES, whereas that of deep neointima did not differ between 
both groups; (3) both superficial and deep neointima of the 
BP-DES presented significantly lower light attenuation and 
backscatter as compared to that of the DP-DES.
Strut coverage in the BP‑ and the DP‑DES
The present study demonstrated the comparable cover-
age percent between BP-DES and DP-DES, which was 
in line with the previous reports. At 3-month follow-up, 
the Ultimaster™ BP-DES and the Synergy™ BP-DES 
achieved similar strut coverage percent of 95.2% and 
94.5%, respectively [2, 10, 11], while the Xience™ DP-
DES and the Resolute™ DP-DES also showed the cover-
age percent of 94.5% and 93.8%, respectively [12, 13]. 
Both previous and the present studies showed comparable 
neointimal coverage percent after implantation of the con-
temporary BP- and DP-DESs assessed by OCT. Neverthe-
less, recent clinical trials (STOP DAPT 2, SENIOR, etc.) 
have proved the feasibility of ultra-short dual antiplatelet 
therapy (1-month DAPT), implying that the OCT coverage 
might not be a suitable surrogate for the vessel healing 
after stent implantation [14]. Not only neointimal cover-
age percent but also objective quality assessment of the 
neointima would be necessary in order to assess the vessel 
healing status more appropriately (Fig. 4).
Interpretation of the light properties
The present study demonstrated the different neointimal 
characteristic between BP- and DP-DES with the dedi-
cated software. We validated the software with histology 
and demonstrated consistently similar relationship on tissue 
characteristics with previous reports [4–6]. Light intensity 
is positively correlated with maturation of the neointimal 
tissue [15]. In animal and human autopsy specimens, mature 
Fig. 3  Imaging examples. Image examples of light property analysis are presented. The dedicated software full-automatically computed, based 
on the original image (A–D), three components of light property analysis (1) light intensity, (2) light attenuation and (3) backscatter
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neointimal tissue with a predominance of smooth muscle 
cells show higher greyscale signal intensity values and lower 
attenuation/backscatter values. Immature tissue with fiber 
rich extracellular matrix, infrequent smooth muscle cells, 
interspersed inflammatory cells, and fibrin show lower sig-
nal intensity values and lower attenuation/backscatter. Lipid-
rich plaque and necrotic core exhibit strong light attenuation 
and backscatter with low intensity values [4–6]. Macrophage 
infiltration and erythrocytes indicate high intensity with high 
attenuation due to their lipid components [15].
It might be challenging to interpret the current results 
based on the previous validation data since no validation 
data was available in the very early phase like ours. There-
fore, we can have only speculative interpretation of the cur-
rent findings as follows. In the present study, the DP-DES 
had higher light intensity and higher light attenuation/back-
scatter values than the BP-DES. High light intensity with 
high attenuation/backscatter might be interpreted as mac-
rophage infiltration or thrombus with erythrocytes whose 
membranes contain a large amount of lipid (40%) [16, 17]. 
Angioscopic observation of the current cohort provided the 
numerically higher rate of thrombus in the DP-DES than in 
the BP-DES (25% vs. 21%, p = 0.357), which might sup-
port this interpretation [7]. Biological responses in stented 
arteries can be divided into three different time phases [18, 
19]: (1) thrombosis/acute inflammation, (2) granulation tis-
sue, and (3) tissue remodeling phase. Theoretical change 
of the light property values is illustrated in Fig. 5. BP-DES 
showed lower light intensity and lower light attenuation/
backscatter values than DP-DES did. Different light intensity 
and attenuation/backscatter between the DP-DES and the 
BP-DES might indicate that, at 3 months after stent implan-
tation, the BP-DES might be in a slightly advanced phase 
as compared with the DP-DES. Note that the changes of 
light property values presented in Fig. 5 is theoretical and 
speculative. Further validation data in acute phase would 
be warranted to interpret our results appropriately. The only 
thing we can say from the current results is that there may 
be some significant differences in the neointimal character-
istics 3 months after DES implantation. Whether the current 
“statistically” significant difference has a clinical impact is 
also yet to be investigated. The recent meta-analysis com-
paring “long-term” clinical data of the BP- and the DP-DES 
demonstrated similar clinical outcomes between both groups 
[20]. However, clinical relevance of the current results with 
very-short term rather than long-term outcomes would be 
of more interest in the current ultra-short DAPT era. The 
present study did not have enough power to assess this point.
Table 4  Determinants of light intensity, attenuation, and backscatter on OCT at 3-month follow-up
The linear regression analysis on light property of the superficial neointima was performed
Variables Light intensity Light attenuation Backscatter
Beta coeffi-
cient
95% CI p value Beta coef-
ficient
95% CI p value Beta coef-
ficient
95% CI p value
BP-DES usage − 44.738 [− 66.415, − 
23.060]
< 0.001 − 0.190 [− 0.273, − 
0.108]
< 0.001 − 0.455 [− 0.646, − 
0.265]
< 0.001
Age (year) 1.050 [− 0.082, 
2.181]
0.069 0.004 [0.000, 0.009] 0.046 0.011 [0.001, 0.021] 0.030
Male gender 20.134 [− 13.17, 
53.438]
0.233 0.044 [− 0.083, 
0.171]





− 2.499 [− 30.421, 
25.423]
0.860 − 0.032 [− 0.138, 
0.074]
0.551 − 0.032 [− 0.278, 
0.213]
0.794
Hypertension 6.099 [− 4.501, 
16.699]




− 4.483 [− 29.312, 
20.347]
0.721 0.004 [− 0.091, 
0.098]
0.938 0.000 [− 0.219, 
0.218]
0.997
Hypertension 6.099 [− 4.501, 
16.699]





16.747 [− 4.655, 
38.149]
0.124 0.015 [− 0.067, 
0.096]
0.719 0.071 [− 0.118, 
0.259]
0.459
Statin use − 12.101 [− 39.664, 
15.462]
0.386 − 0.061 [− 0.166, 
0.044]
0.252 − 0.107 [− 0.350, 
0.135]
0.382
Prasugrel use − 3.751 [− 25.787, 
18.286]
0.737 − 0.034 [− 0.118, 
0.050]





0.025 [− 0.429, 
0.480]
0.912 0.000 [− 0.002, 
0.002]
0.959 0.000 [− 0.004, 
0.004]
0.935
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Factors associated with neoatherosclerotic change
Several factors may be associated with the vessel healing 
process after implantation of DES. In the previous litera-
tures, DES use as compared to bare metal stent, diabetes, 
inadequate lipid control, and native atherosclerosis progres-
sion were associated with neoatherosclerosis [21–24]. Pro-
cedural factors and clinical presentation would also have a 
significant impact on the neointimal characteristics repre-
sented by the light property values [25, 26]. The effect of 
BP-DES was assessed with the multivariate linear regres-
sion model with an adjustment including following factors: 
sex, acute coronary syndrome (angina type), hypertension, 
diabetes mellitus, statin use, age, current smoker, follow-
up duration, and prasugrel use (Table 4). The present study 
demonstrated that, usage of BP-DES had, at least in the very 
short-term follow-up, a major impact on light intensity, light 
attenuation and backscatter, whereas other factors had a lim-
ited impact. A prospective and long-term clinical association 
of the patients’ factors with the neointimal characteristics 
should be investigated.
Clinical Implication
The present study demonstrated the comparable coverage per-
cent and neointimal thickness at 3-month follow-up. However, 
the light property analysis demonstrated that the light charac-
teristics of the neointima following implantation of BP- and 
DP-DES were significantly different. These results suggested 
the importance of not only percent coverage but also quality 
assessment of the neointima when we evaluate the vessel heal-
ing on OCT especially at very acute phase.
In our recent clinical practice, duration of DAPT is get-
ting shorter based on the results of short DAPT studies [14, 
27]. Imaging assessments particularly by OCT can provide 
precise insights into the vessel healing and will be helpful to 
establish a background of ultra-short DAPT strategy. Serial 
imaging assessment at very early phase (1, 2, 3 months) is 
Fig. 4  Neointimal quality assessment by light property analysis. 
Neointimal quality was quantitatively assessed for BP-DES (red) 
and DP-DES (blue) by light property analysis including light inten-
sity (A), light attenuation (B), and backscatter (C). Neointimal area 
was separated into two parts: (1) superficial neointima, and (2) deep 
neointima
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required to elucidate the vessel healing process of the con-
temporary DES. Quantitative light property analysis would 
be useful and advantageous over visual assessment to evalu-
ate the quality of tissue coverage.
Study strength and limitation
The methodology we employed in the present analysis was 
highly objective and reproducible, making the results repro-
ducible and reliable. However, some limitations should to 
be acknowledged. First, study design was a single center 
observational study and the sample size was relatively small, 
albeit the well-balanced patient demographics. Second, only 
one time point assessment (3 months) could not provide in-
depth insights into the difference in progression of neointi-
mal coverage between BP- and DP-DES. Third, difference 
amongst the analyzed stents [Synergy™, Ultimaster™, 
Xience™, Resolute Integrity™, and Resolute Onyx™] is 
not only the polymer degradation type but also strut design, 
strut shape, strut material, strut thickness, polymer coating 
type (abluminal coating, circumferential coating), poly-
mer degradation speed, drug type, drug releasing speed, 
drug concentration, etc. These confounders were not fully 
adjusted in the present analysis. Along the same lines, both 
BP-DES and DP-DES still keep polymer at 3 months follow-
up, although the bioresorption process presumably influence 
on the neointimal characteristics. Lastly, the direct impact of 
these findings on clinical outcome remains to be elucidated. 
We plan to assess the light property of the neointima again 
at the chronic phase (2 years) in the RESTORE registry 
and evaluate clinical impacts of this imaging surrogates on 
2-year outcomes. Due to the inherent limitations of the cur-
rent study design, the results would be hypothesis-generating 
and should be interpreted with caution. Further prospective 
Fig. 5  Theoretical change of the light property values in acute 
phase. Vascular healing process following vessel injury by metal-
lic stent implantation was previously reported based on the autopsy 
data [18, 19]. The vessel healing process can be divided into 3 dif-
ferent phases: (1) thrombosis/acute inflammation, (2) granulation tis-
sue, and (3) tissue remodeling phase. Considering the predominant 
cellular components in each phase, we can speculate the theoretical 
changes of the light property values as follows: Phase 1: Thrombo-
sis/acute inflammation (1–30 days) Endothelium injury by stent 
implantation leads to the response of the activation of platelets and 
their deposition at the site of the lesion, with recruitment of circu-
lating leucocytes. The platelet/fibrin/erythrocyte deposition occurs 
in the first 24–48 hours. Acute inflammatory cells can be identified 
within the platelet/fibrin aggregates around the stent struts. Erythro-
cyte contains a large amount of lipid in its membrane (40%) [16]. In 
this phase, thrombus with erythrocytes and inflammatory cells would 
indicate high intensity with high attenuation. Phase 2: Granulation 
tissue (14–90 days) The endothelial cells proliferate and migrate over 
the injured areas while smooth muscle cells and macrophages replace 
the fibrin clot with granulation tissue. The newly formed vascularized 
tissue includes macrophages which are responsible for phagocytosis 
of cell debris as well as secretion of growth factors, chemokines and 
cytokines. Light intensity and attenuation/backscatter would theoreti-
cally decrease in this phase. Phase 3: Tissue remodeling phase (3–9 
months) The hallmark of this phase is the modification of smooth 
muscle cells activated by growth factors/cytokines produced by the 
injured endothelium and media, platelets, and infiltrated inflamma-
tory cells as well as by the compressive forces generated in the ves-
sel wall by the stent placement along with low shear stress induced 
by stent struts. Neointimal smooth muscle cells proliferate during 3–9 
months with production of varying amount of extracellular matrix. 
The first phase of matrix formation is the formation of provisional 
matrix which is formed by the plasma proteins such as fibrin, fibrin-
ogen, and fibronectin. In early phase, fiber rich extracellular matrix, 
infrequent smooth muscle cells, and interspersed inflammatory cells 
would show lower signal intensity values and lower attenuation/back-
scatter. In late phase, mature neointimal tissue with a predominance 
of smooth muscle cells would show higher greyscale signal intensity 
values and lower attenuation/backscatter values
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randomized trials would be warranted to obtain a robust 
conclusion.
Conclusion
Almost complete coverage at 3 months in both contemporary 
BP- and DP-DES would support the ultra-short DAPT strat-
egy in the upcoming decade. Nevertheless, there was a sig-
nificant difference in the neointimal characteristics on OCT 
light property 3 months after BP- vs. DP-DES implantation. 
Further prospective randomized trials should be conducted 
to re-evaluate the current hypothesis-generating results and 
to investigate the clinical significance of the present imag-
ing results.
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